secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-08-10T20:30:43+00:00
Accession:  0001193125-26-342495
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics reports 2Q26 net loss $26.8M; advances VMT-α-NET toward Phase 3
--------------------------------------------------------------------------------

- Net loss $26.8M ($0.22/share) vs $21.5M ($0.29) in 2Q25; R&D expenses $21.5M, up from $16.6M.
- Cash and investments $237M at 6/30/26, up from $145M at 12/31/25; runway into late 2027.
- VMT-α-NET: 76 NET patients treated; Phase 3 planned at cumulative 20 mCi dose; site activation targeted year-end 2026.
- VMT01: 27 patients; 2 partial responses at 3.0 mCi monotherapy; nivolumab combo cohort progressing.
- Appointed Paul Lyne, Ph.D. as Chief Science Officer in July 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526342495/0001193125-26-342495-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526342495/catx-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-342495

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer